Interim Report Q2 2021

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the second quarter 2021. Total revenue amounted to SEK 3,211 M, 14 per cent growth at CER compared with the same period 2020. EBITA was SEK 922 M, resulting in an EBITA margin of 29 per cent.

April – June

• Total revenue of SEK 3,211 M (3 070), 5 per cent growth and 14 per cent at CER
• EBITA¹ was SEK 922 M (1,018), with an EBITA margin¹ of 29 per cent (33)
• Earnings per share (EPS) before dilution of SEK 0.91 (0.96)
• Haematology sales were SEK 2,125 M (2,037), 12 per cent growth at CER
• Sales for Elocta® were SEK 1,005 M (1,040), 2 per cent growth at CER
• Sales for Alprolix® were SEK 438 M (363), 27 per cent growth at CER
• Doptelet® grew by 42 per cent at CER to SEK 230 M
• Immunology sales were SEK 752 M (714), Gamifant® grew by 46 per cent at CER to SEK 168 M (132)
• Cash flow from operating activities of SEK 1,393 M (1,942)

January – June

• Total revenue of SEK 6,872 M (7,709), -11 per cent and -2 per cent at CER
• EBITA¹ was SEK 2,406 M (3,191), with an EBITA margin¹ of 35 per cent (41)
• EPS before dilution of SEK 3.27 (4.98)
• Haematology sales were SEK 4,003 M (4,431), -3 per cent at CER
• Sales for Elocta were SEK 1,861 M (2,399), -18 per cent at CER
• Sales for Alprolix were SEK 851 M (851), 6 per cent growth at CER
• Doptelet grew by 88 per cent at CER to SEK 411 M
• Immunology sales were SEK 2,305 M (2,514), Gamifant grew by 47 per cent at CER to SEK 301 M (236)
• Cash flow from operating activities of SEK 3,092 (3,828)
   

Significant events after the reporting period

• In July, Kineret® was submitted to EMA with a proposed indication for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia who are at risk of developing severe respiratory failure
   

Outlook 2021 – unchanged

• Revenue for the full-year 2021 is expected to be in the range of SEK 14,000–15,000 M
• EBITA margin is expected to be in the range of 30–35 per cent of revenue
   

Guido Oelkers, CEO and President:

“We ended the second quarter on a positive note and are back to double-digit growth. Our figures are still impacted by the COVID-19 pandemic and its related restrictions and lock-downs, but as restrictions have eased, we have started to see improved market conditions. During the quarter, we advanced the R&D portfolio such as pegcetacoplan and efanesoctocog alfa, as well as anakinra (Kineret) for the treatment of COVID-19 pneumonia.”

Financial Summary

Telephone conference

Investors, financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, today at 13:00 CEST. The event will be hosted by Sobi’s CEO and President, Guido Oelkers, and the presentation will be held in English.

The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on Sobi’s website prior to the telephone conference.

To participate in the telephone conference, please call:

SE: +46 8 566 426 92 (Direct)

UK: +44 3 333 009 260 (Direct)

US: +1 631 913 1422 PIN: 83892913#

Click here to go to the live webcast

After the live event the webcast will be available on-demand via the same link.
---

About Sobi™

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Sobi employs approximately 1,500 people across Europe, North America, the Middle East, Russia and Asia. In 2020, Sobi’s revenues amounted to SEK 15.3 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.
 

This information is information that Swedish Orphan Biovitrum AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out below, at 08:00 CEST on 21 July 2021.

For more information, please contact:

Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
[email protected]

Maria Kruse, Corporate Communication & Investor Relations
+ 46 767 248 830
[email protected]